Supervised setting
SPRAVATO® is self-administered under healthcare-provider supervision in a SPRAVATO REMS-certified healthcare setting. It is not for unsupervised home use.
Patient information
SPRAVATO® (esketamine) information
SPRAVATO® is a prescription nasal spray with specific FDA-approved uses, safety requirements, and supervised treatment procedures. A clinical evaluation helps determine whether discussing this option is appropriate.
FDA-approved uses
What it may be prescribed for
SPRAVATO® is FDA-approved for adults with treatment-resistant depression (TRD), with or without an oral antidepressant.
For depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions, it is used with an oral antidepressant.
It is not known to prevent suicide or reduce suicidal thoughts or actions, and it does not replace hospitalization when a healthcare provider determines hospitalization is needed.
What treatment involves
This is not an at-home medication.
Observation and transportation
People are monitored for at least 2 hours after each administration. Plan transportation home; do not drive, operate machinery, or do activities requiring full alertness until the next day after restful sleep.
Safety considerations
Important risks to discuss.
SPRAVATO® can cause sedation, dissociation, increases in blood pressure, respiratory depression, and misuse or abuse. Your healthcare provider can explain the complete safety information and whether other factors in your health history need attention.
Learn more or request an evaluation conversation.
For complete prescribing and safety information, review the official manufacturer resources and discuss questions with a healthcare provider.